MCID: SBS004
MIFTS: 51

Substance Dependence

Categories: Mental diseases

Aliases & Classifications for Substance Dependence

MalaCards integrated aliases for Substance Dependence:

Name: Substance Dependence 12 51 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9973
NCIt 46 C35458
SNOMED-CT 64 103326000 255338002

Summaries for Substance Dependence

Disease Ontology : 12 A substance-related disorder that involves the continued use of alcohol or other drugs despite problems related to use of the substance.

MalaCards based summary : Substance Dependence is related to smoking as a quantitative trait locus 3 and chronic pain. An important gene associated with Substance Dependence is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Transmission across Chemical Synapses and Peptide ligand-binding receptors. The drugs Ethanol and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and liver, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 72 Substance dependence also known as drug dependence is an adaptive state that develops from repeated drug... more...

Related Diseases for Substance Dependence

Diseases related to Substance Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Related Disease Score Top Affiliating Genes
1 smoking as a quantitative trait locus 3 30.2 CHRNA3 CHRNA5
2 chronic pain 30.1 CNR1 OPRM1
3 antisocial personality disorder 30.0 DRD2 MAOA SLC6A3 SLC6A4
4 drug dependence 29.9 BDNF CNR1 DRD2 DRD3 OPRD1 OPRK1
5 borderline personality disorder 29.7 BDNF HTR1B MAOA SLC6A4
6 anxiety 29.5 BDNF CNR1 MAOA SLC6A3 SLC6A4
7 phobic disorder 29.5 MAOA OPRK1 SLC6A4
8 tobacco addiction 29.4 CHRNA3 CHRNA5 CHRNB4 DRD2 MAOA OPRM1
9 bulimia nervosa 1 29.3 BDNF HTR1B MAOA SLC6A4
10 generalized anxiety disorder 29.2 BDNF DRD2 MAOA SLC6A4
11 conduct disorder 29.2 DRD2 DRD4 DRD5 MAOA SLC6A3 SLC6A4
12 heroin dependence 29.1 BDNF DRD2 DRD4 OPRD1 OPRM1 SLC6A3
13 eating disorder 29.0 BDNF CNR1 DRD2 POMC SLC6A3 SLC6A4
14 post-traumatic stress disorder 29.0 BDNF CNR1 DRD2 MAOA SLC6A4
15 panic disorder 29.0 BDNF MAOA POMC SLC6A4
16 psychotic disorder 28.6 BDNF DRD2 DRD3 DRD4 SLC6A3 SLC6A4
17 mood disorder 28.4 BDNF DRD2 DRD4 HTR1B MAOA POMC
18 personality disorder 28.3 BDNF DRD2 DRD3 DRD4 HTR1B MAOA
19 pathological gambling 28.2 DRD2 DRD3 DRD4 MAOA SLC6A3 SLC6A4
20 bipolar disorder 28.1 BDNF DRD2 DRD3 DRD4 DRD5 MAOA
21 disease of mental health 27.5 BDNF CNR1 DRD2 DRD3 DRD4 MAOA
22 attention deficit-hyperactivity disorder 27.5 BDNF DRD2 DRD3 DRD4 DRD5 HTR1B
23 cocaine dependence 27.4 CHRNA3 CHRNA5 DRD2 DRD3 OPRD1 OPRK1
24 substance abuse 27.4 BDNF DRD2 DRD3 DRD4 DRD5 HTR1B
25 schizophrenia 27.3 BDNF CNR1 DRD2 DRD3 DRD4 DRD5
26 migraine with or without aura 1 27.1 CNR1 DRD2 DRD3 DRD4 DRD5 HTR1B
27 alcohol dependence 26.3 ADH1A ADH4 BDNF CNR1 DRD2 DRD3
28 neonatal abstinence syndrome 10.5 OPRD1 OPRK1 OPRM1
29 morphine dependence 10.5 OPRD1 OPRK1 OPRM1
30 cyclic vomiting syndrome 10.5 CNR1 OPRM1
31 opioid addiction 10.4 DRD2 OPRD1 OPRK1 OPRM1
32 withdrawal disorder 10.4 CNR1 OPRM1 POMC
33 cannabis abuse 10.4 BDNF CHRNA3 CNR1
34 pain agnosia 10.3 CNR1 OPRK1 OPRM1 POMC
35 agnosia 10.3 CNR1 OPRK1 OPRM1 POMC
36 amnestic disorder 10.3 BDNF CNR1 POMC
37 uremic pruritus 10.2 CNR1 OPRK1
38 alcohol-induced mental disorder 10.2 DRD2 SLC6A3 SLC6A4
39 alcohol use disorder 10.2 DRD2 SLC6A4
40 alcoholic psychosis 10.1 DRD2 SLC6A3 SLC6A4
41 tic disorder 10.1 DRD2 DRD4 DRD5 SLC6A3
42 social phobia 10.1 DRD2 MAOA SLC6A4
43 cocaine abuse 10.1 DRD2 SLC6A3 SLC6A4
44 agoraphobia 10.1 MAOA OPRK1 SLC6A4
45 premature ejaculation 10.0 HTR1B SLC6A3 SLC6A4
46 polysubstance abuse 10.0 CNR1 DRD2 DRD3
47 atypical depressive disorder 10.0 MAOA SLC6A4
48 alexithymia 10.0
49 retrograde amnesia 10.0 POMC SLC6A4
50 brunner syndrome 10.0 HTR1B MAOA SLC6A4

Graphical network of the top 20 diseases related to Substance Dependence:



Diseases related to Substance Dependence

Symptoms & Phenotypes for Substance Dependence

MGI Mouse Phenotypes related to Substance Dependence:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 SLC6A4 OPRK1 OPRM1 POMC SLC6A3 OPRD1
2 homeostasis/metabolism MP:0005376 10.17 SLC6A4 OPRK1 OPRM1 POMC SLC6A3 OPRD1
3 nervous system MP:0003631 10.06 SLC6A4 OPRK1 OPRM1 POMC SLC6A3 OPRD1
4 endocrine/exocrine gland MP:0005379 10.02 SLC6A4 OPRK1 OPRM1 POMC SLC6A3 DRD2
5 digestive/alimentary MP:0005381 10.01 OPRK1 OPRM1 DRD2 BDNF DRD3 CHRNA3
6 integument MP:0010771 9.96 SLC6A4 OPRK1 OPRM1 POMC SLC6A3 OPRD1
7 adipose tissue MP:0005375 9.93 OPRM1 POMC CNR1 DRD2 DRD3 HTR1B
8 no phenotypic analysis MP:0003012 9.56 OPRD1 OPRM1 POMC DRD2 BDNF CHRNA3
9 taste/olfaction MP:0005394 8.92 SLC6A3 CNR1 DRD2 BDNF

Drugs & Therapeutics for Substance Dependence

Drugs for Substance Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 130)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
2
Dopamine Approved Phase 4,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
4
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 1 50-36-2 446220 5760
5
Heroin Approved, Illicit, Investigational Phase 4,Phase 1 561-27-3 5462328
6
Nicotine Approved Phase 4,Phase 2,Phase 3,Phase 1 54-11-5 89594 942
7
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
8
Ribavirin Approved Phase 4 36791-04-5 37542
9
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
10
Bupropion Approved Phase 4,Phase 2 34911-55-2, 34841-39-9 444
11
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
12
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 1,Phase 2 300-62-9 3007 5826
13
Methadone Approved Phase 4,Phase 3,Phase 1 76-99-3 4095
14
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
15
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2 16590-41-3 5360515
16
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 52485-79-7 644073 40400
17
Allopurinol Approved Phase 4 315-30-0 2094
18
Choline Approved, Nutraceutical Phase 4 62-49-7 305
19 Analgesics Phase 4,Phase 3,Phase 1
20 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
21 Adrenergic Agents Phase 4,Phase 2,Phase 1
22 Central Nervous System Stimulants Phase 4,Phase 2,Phase 1
23 Narcotics Phase 4,Phase 3,Phase 2,Phase 1
24 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Tranquilizing Agents Phase 4,Phase 3,Phase 2
26 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
27 Analgesics, Opioid Phase 4,Phase 3,Phase 1
28 Dopamine Agents Phase 4,Phase 2,Phase 1,Early Phase 1
29 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 1
31 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Anti-Infective Agents, Local Phase 4,Phase 3,Phase 2,Phase 1
33 Psychotropic Drugs Phase 4,Phase 3,Phase 2
34 Antipsychotic Agents Phase 4,Phase 3,Phase 2
35 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Quetiapine Fumarate Phase 4 111974-72-2
37
Serotonin Phase 4,Phase 3,Phase 2 50-67-9 5202
38 interferons Phase 4
39 Serotonin Agents Phase 4,Phase 3,Phase 2
40 Serotonin Antagonists Phase 4,Phase 2
41 Serotonin Uptake Inhibitors Phase 4,Phase 3
42 Narcotic Antagonists Phase 4,Phase 3,Phase 2
43 GABA Agents Phase 4,Phase 2
44 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
45 Cytidine Diphosphate Choline Phase 4
46 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
47 Nootropic Agents Phase 4,Phase 2
48 Vasoconstrictor Agents Phase 4,Phase 2,Phase 1
49 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
50 Anesthetics Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 119)

# Name Status NCT ID Phase Drugs
1 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Unknown status NCT01155544 Phase 4
2 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
3 Chemical Dependency and Smoking Cessation: Patient's Views - 1 Completed NCT00051883 Phase 4
4 Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse Completed NCT00573534 Phase 4 Vyvanse
5 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4 Divalproex ER
6 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
7 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
8 Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation Completed NCT00484692 Phase 4 sustained-release bupropion (Zyban(R))
9 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
10 Improving Hepatitis C Treatment in Injection Drug Users Completed NCT00148031 Phase 4 Pegylated Interferon and Ribavirin
11 Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs. in Specialized Chemical Dependence Treatment: A Pilot Trial Terminated NCT00461890 Phase 4 Injectable Naltrexone
12 Allopurinol Maintenance Study for Bipolar Disorder Terminated NCT00732251 Phase 4 Allopurinol
13 Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices Completed NCT00657397 Phase 3 Methadone
14 Adolescent Outpatient and Continuing Care Study Completed NCT01381133 Phase 3
15 Maternal Acupuncture for Substance Abuse Completed NCT00225316 Phase 3
16 Incentive Programs for Female Substance Abusers Who Smoke - 3 Completed NCT00064922 Phase 2, Phase 3
17 Addiction Health Evaluation And Disease Management (AHEAD) Study Completed NCT00278447 Phase 3
18 A Novel Approach to Cardiovascular Health by Optimizing Risk Management (ANCHOR) Completed NCT01620996 Phase 3
19 Olanzapine Treatment of Patients With Bipolar I Disorder Completed NCT00510146 Phase 3 Olanzapine;Placebo
20 RCT Comparing Methadone and Buprenorphine in Pregnant Women Completed NCT00271219 Phase 3 Methadone;Buprenorphine
21 A Dose Ranging Study of Modafinil for Methamphetamine Dependence Unknown status NCT00630097 Phase 2 modafinil
22 Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction Unknown status NCT00609089 Phase 1, Phase 2
23 Evaluation of Re-Entry Values and Mindfulness Program (REVAMP) With Jail Inmates Unknown status NCT01378923 Phase 1, Phase 2
24 A Behavioral Trial for the Treatment of Methamphetamine Dependence. - 1 Unknown status NCT00033124 Phase 2
25 Memory Reconsolidation Blockade for Treating Drug Addiction Completed NCT01634347 Phase 2 Propranolol and memory reactivation;Placebo and memory reactivation
26 Cognitive Remediation and Work Therapy in the Initial Phase of Substance Abuse Treatment Completed NCT01410110 Phase 2
27 Group Therapy for Women Prisoners With Comorbid Substance Use and Depression Completed NCT00606996 Phase 2
28 Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients Completed NCT00295139 Phase 2
29 D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals Completed NCT00780442 Phase 2 d-cycloserine
30 Atomoxetine for the Treatment of Cannabis Dependence Completed NCT00167297 Phase 2 Atomoxetine
31 The MEADOW PROJECT (Mending the Effects of Alcohol and Depression on Women) and The Bridge Program (Connecting Recovery Treatment and Behavioral Health) Completed NCT00851669 Phase 2
32 Psychopharmacology for Cocaine Dependence - Buspirone Completed NCT01267292 Phase 2 Buspirone;Placebo for Buspirone;Methylphenidate;Placebo for Methylphenidate
33 Validating Interventions for Diverse Adolescents Completed NCT01018654 Phase 2
34 Efficacy Trial of Warrior Check-Up Completed NCT01128140 Phase 2
35 Reinforcement of Abstinence and Continuing Care in Substance Abuse Treatment Completed NCT00288886 Phase 2
36 Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse Completed NCT00248092 Phase 1, Phase 2 NRP104
37 Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Completed NCT00247572 Phase 2 NRP104
38 VIVITROL as a Treatment for Cocaine and Alcohol Dependence Completed NCT00777062 Phase 2 VIVITROL (Naltrexone extended-release injectable suspension);Placebo
39 Bupropion for the Treatment of Methamphetamine Dependence - 1 Completed NCT00069251 Phase 2 Bupropion
40 Ondansetron for the Treatment of Methamphetamine Dependence - 1 Completed NCT00040053 Phase 2 Ondansetron
41 Topiramate for the Treatment of Methamphetamine Dependence - 1 Completed NCT00345371 Phase 2 Topiramate;Placebo Oral Tablet
42 Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence Completed NCT00520286 Phase 2 Modafinil;Placebo
43 Vigabatrin for Treatment of Cocaine Dependence Completed NCT00611130 Phase 2 vigabatrin;placebo
44 Distress Tolerance Treatment for Substance Users Recruiting NCT01741415 Phase 2
45 Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use Terminated NCT00430573 Phase 2 D-cycloserine;Placebo
46 Relapse Prevention Study in Newly Abstinent Smokers Withdrawn NCT00793468 Phase 2 GSK598809;Nicotine Replacement Transdermal Patch;Placebo
47 "The Evaluation of Stimulant Withdrawal" Withdrawn NCT00442923 Phase 2 Coreg
48 Oxytocin in Opiate Dependence: A Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence Unknown status NCT02052258 Phase 1 Oxytocin
49 To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334 Completed NCT00513279 Phase 1 GSK618334;GSK618334 matching placebo tablets
50 Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809 Completed NCT00437632 Phase 1 GSK598809;Placebo;Caffeine

Search NIH Clinical Center for Substance Dependence

Genetic Tests for Substance Dependence

Anatomical Context for Substance Dependence

MalaCards organs/tissues related to Substance Dependence:

38
Brain, Testes, Liver, Eye, Bone

Publications for Substance Dependence

Articles related to Substance Dependence:

(show top 50) (show all 395)
# Title Authors Year
1
Corrigendum to "Mindfulness-oriented recovery enhancement versus CBT for co-occurring substance dependence, traumatic stress, and psychiatric disorders: Proximal outcomes from a pragmatic randomized trial" [Behav. Res. Ther. 77 (2016) 7-16]. ( 28964403 )
2018
2
Nurse Anesthetists' Reflections on Caring for Patients With Previous Substance Dependence: Balancing Between Professionalism and Preconceptions. ( 29362049 )
2018
3
Polypharmacy and risk of falls and fractures for patients with HIV infection and substance dependence. ( 29034725 )
2018
4
Development of a Contextualized Version of the Multiple Errands Test for People with Substance Dependence. ( 29041993 )
2017
5
Behavioral approach and orbitofrontal cortical activity during decision-making in substance dependence. ( 28934666 )
2017
6
Targeting Phosphodiesterases in Pharmacotherapy for Substance Dependence. ( 28956341 )
2017
7
The effects of patient and physician characteristics on early outpatient satisfaction with substance dependence care: results of the SUBUSQOL study. ( 28507432 )
2017
8
Lifetime and recent alcohol use and bone mineral density in adults with HIV infection and substance dependence. ( 28445303 )
2017
9
Depression and severity of substance dependence among heroin dependent patients with ADHD symptoms. ( 27997065 )
2017
10
Quality measurers of therapeutic communities for substance dependence: an international collaborative study survey in Latin America. ( 29262838 )
2017
11
Substance dependence among those without symptoms of substance abuse in the World Mental Health Survey. ( 28211594 )
2017
12
Patient experiences questionnaire for interdisciplinary treatment for substance dependence (PEQ-ITSD): reliability and validity following a national survey in Norway. ( 28219361 )
2017
13
Polypharmacy and risk of non-fatal overdose for patients with HIV infection and substance dependence. ( 28847449 )
2017
14
Does Emotion Dysregulation Mediate the Relationship between Early Maltreatment and Later Substance Dependence? Findings of the CANSAS Study. ( 27438781 )
2016
15
Integrated Exposure-Based Therapy for Co-Occurring Post Traumatic Stress Disorder (PTSD) and Substance Dependence: Predictors of Change in PTSD Symptom Severity. ( 27854264 )
2016
16
An association study revealed substantial effects of dominance, epistasis and substance dependence co-morbidity on alcohol dependence symptom count. ( 27151647 )
2016
17
Lifetime history of traumatic events in a young adult Mexican American sample: Relation to substance dependence, affective disorder, acculturation stress, and PTSD. ( 27569652 )
2016
18
Comorbid depression, antisocial personality, and substance dependence: Relationship with delay discounting. ( 26846198 )
2016
19
Attention deficit hyperactivity disorder symptoms, type of offending and recidivism in a prison population: The role of substance dependence. ( 27455899 )
2016
20
Which adolescents develop persistent substance dependence in adulthood? Using population-representative longitudinal data to inform universal risk assessment. ( 26620720 )
2016
21
Mindfulness-Oriented Recovery Enhancement versus CBT for co-occurring substance dependence, traumatic stress, and psychiatric disorders: Proximal outcomes from a pragmatic randomized trial. ( 26701171 )
2016
22
Use of Family CAGE-AID questionnaire to screen the family members for diagnosis of substance dependence. ( 27748296 )
2016
23
Mentalization-based therapy adherence and competence stimulates in-session mentalization in psychotherapy for borderline personality disorder with co-morbid substance dependence. ( 27093128 )
2016
24
The Positive and Negative Syndrome Scale (PANSS): A Three-Factor Model of Psychopathology in Marginally Housed Persons with Substance Dependence and Psychiatric Illness. ( 26999280 )
2016
25
A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care. ( 27733137 )
2016
26
Associations between compulsive buying and substance dependence/abuse, major depressive episodes, and generalized anxiety disorder among men and women. ( 27215919 )
2016
27
Disturbing sleep and sleepfulness during recovery from substance dependence in residential rehabilitation settings. ( 27917494 )
2016
28
Alcohol-Dependent Subjects Show Different Personality Traits Compared With Subjects With Multiple Substance Dependence: Preliminary Data. ( 26079976 )
2015
29
Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. ( 26392368 )
2015
30
Effectiveness of Computer-Assisted Therapy for Substance Dependence Using Breaking Free Online: Subgroup Analyses of a Heterogeneous Sample of Service Users. ( 26543918 )
2015
31
Metacognitive and Meta-Emotional Styles in Patients With Alcohol and the Other Substance Dependence. ( 26495260 )
2015
32
Emergency department use and hospitalizations among homeless adults with substance dependence and mental disorders. ( 26242968 )
2015
33
Temperament and character dimensions assessed in general population, in individuals with psychoactive substance dependence and in young male conscripts. ( 25687735 )
2015
34
Epidemiological Studies of Substance Dependence and Abuse in Adults. ( 26417548 )
2015
35
Psychoactive Substance Dependence: A Dentist's Challenge. ( 26556258 )
2015
36
Impaired Decision-Making, Higher Impulsivity, and Drug Severity in Substance Dependence and Pathological Gambling. ( 25918968 )
2015
37
Engagement and substance dependence in a primary care-based addiction treatment program for people infected with HIV and people at high-risk for HIV infection. ( 26298399 )
2015
38
The prescription of addiction medications after implementation of chronic care management for substance dependence in primary care. ( 25524751 )
2015
39
Posttraumatic stress disorder symptoms and risky behaviors among trauma-exposed inpatients with substance dependence: The influence of negative and positive urgency. ( 26278196 )
2015
40
The advantages and barriers in the implementation of a substance dependence treatment information system (SDTIS). ( 26941816 )
2015
41
Investigating the factor structure of the Illness Perception Questionnaire-revised for substance dependence among injecting drug users in China. ( 25649986 )
2015
42
The Comorbid and Individual Impacts of Maternal Depression and Substance Dependence on Parenting and Child Behavior Problems. ( 26478656 )
2015
43
Reward salience and risk aversion underlie differential ACC activity in substance dependence. ( 26106528 )
2015
44
Relationship between drug dreams, affect, and craving during treatment for substance dependence. ( 25700139 )
2015
45
Comparing Sensory Information Processing and Alexithymia between People with Substance Dependency and Normal. ( 26885354 )
2015
46
Medical diagnoses associated with substance dependence among inpatients at a large urban hospital. ( 26107402 )
2015
47
A Pilot Study of Seeking Safety in a Sample of German Women Outpatients with Substance Dependence and Posttraumatic Stress Disorder. ( 26514284 )
2015
48
Dissecting ancestry genomic background in substance dependence genome-wide association studies. ( 26267224 )
2015
49
A study of the substance dependence effect of the ethanolic extract and iridoid-rich fraction from Valeriana jatamansi Jones in mice. ( 26600719 )
2015
50
Women with comorbid substance dependence and psychiatric disorders in Sweden: a longitudinal study of hospital care utilization and costs. ( 26048811 )
2015

Variations for Substance Dependence

Expression for Substance Dependence

Search GEO for disease gene expression data for Substance Dependence.

Pathways for Substance Dependence

Pathways related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 CHRNA3 CHRNA5 CHRNB4 MAOA SLC6A3 SLC6A4
2
Show member pathways
12.7 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2 DRD3
3
Show member pathways
12.67 BDNF DRD2 DRD3 DRD4 DRD5
4
Show member pathways
12.23 CHRNA3 CHRNB4 DRD2 DRD3 DRD4 DRD5
5 12.21 DRD2 DRD3 DRD4 DRD5
7
Show member pathways
12.14 BDNF DRD2 DRD5 HTR1B
8 12.01 BDNF CHRNB4 MAOA SLC6A4
9 11.83 HTR1B MAOA SLC6A4
10
Show member pathways
11.83 BDNF DRD2 MAOA SLC6A3
11 11.79 MAOA OPRD1 OPRM1 POMC
12 11.78 CNR1 DRD3 DRD4
13
Show member pathways
11.72 DRD2 DRD3 DRD4 DRD5 HTR1B
14
Show member pathways
11.69 CHRNA3 CHRNA5 CHRNB4
15
Show member pathways
11.62 ADH1A ADH4 MAOA
16
Show member pathways
11.56 CHRNA3 CHRNA5 DRD2 DRD3 DRD4
17
Show member pathways
11.29 MAOA SLC6A3 SLC6A4
18 11.03 HTR1B MAOA SLC6A4
19
Show member pathways
10.96 MAOA SLC6A3 SLC6A4
20 10.84 DRD2 DRD3 DRD5
21
Show member pathways
10.77 ADH4 MAOA
22
Show member pathways
10.43 CHRNA3 CHRNB4

GO Terms for Substance Dependence

Cellular components related to Substance Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.78 CNR1 DRD2 OPRM1 SLC6A3
2 postsynaptic membrane GO:0045211 9.73 CHRNA3 CHRNA5 CHRNB4 OPRD1
3 membrane raft GO:0045121 9.72 CNR1 OPRD1 OPRM1 SLC6A3 SLC6A4
4 axon terminus GO:0043679 9.58 DRD2 OPRD1 OPRK1
5 dendrite membrane GO:0032590 9.46 OPRD1 OPRM1
6 acetylcholine-gated channel complex GO:0005892 9.43 CHRNA3 CHRNA5 CHRNB4
7 neuron projection GO:0043005 9.43 CHRNB4 OPRD1 OPRK1 OPRM1 SLC6A3 SLC6A4
8 integral component of plasma membrane GO:0005887 9.4 CHRNB4 CNR1 DRD2 DRD3 DRD4 DRD5
9 integral component of membrane GO:0016021 10.24 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2 DRD3
10 plasma membrane GO:0005886 10.03 ADH1A CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2

Biological processes related to Substance Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.96 OPRD1 OPRK1 OPRM1 POMC
2 cellular calcium ion homeostasis GO:0006874 9.91 DRD3 DRD4 DRD5
3 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.91 HTR1B OPRD1 OPRK1 OPRM1
4 sensory perception of pain GO:0019233 9.9 CNR1 OPRD1 OPRK1 OPRM1
5 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.88 OPRD1 OPRK1 OPRM1
6 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.88 CNR1 HTR1B OPRD1 OPRM1
7 excitatory postsynaptic potential GO:0060079 9.88 CHRNA3 CHRNA5 CHRNB4 DRD2 OPRM1
8 social behavior GO:0035176 9.87 DRD3 DRD4 SLC6A4
9 regulation of sensory perception of pain GO:0051930 9.85 OPRD1 OPRK1 OPRM1
10 eating behavior GO:0042755 9.85 OPRD1 OPRK1 OPRM1
11 synaptic transmission, cholinergic GO:0007271 9.84 CHRNA3 CHRNA5 CHRNB4
12 negative regulation of adenylate cyclase activity GO:0007194 9.84 DRD2 DRD3 DRD4 OPRM1
13 arachidonic acid secretion GO:0050482 9.83 DRD2 DRD3 DRD4
14 negative regulation of blood pressure GO:0045776 9.83 CNR1 DRD2 DRD3 DRD5
15 regulation of dopamine secretion GO:0014059 9.82 DRD2 DRD3 HTR1B
16 synaptic transmission, dopaminergic GO:0001963 9.82 DRD2 DRD3 DRD5
17 negative regulation of protein secretion GO:0050709 9.81 DRD2 DRD3 DRD4
18 negative regulation of cAMP biosynthetic process GO:0030818 9.81 DRD4 HTR1B OPRM1
19 behavioral response to ethanol GO:0048149 9.8 DRD2 DRD4 OPRM1
20 dopamine metabolic process GO:0042417 9.8 DRD2 DRD3 DRD4
21 response to amphetamine GO:0001975 9.8 DRD2 DRD3 DRD4 DRD5
22 prepulse inhibition GO:0060134 9.79 DRD2 DRD3 SLC6A3
23 G-protein coupled receptor internalization GO:0002031 9.78 DRD2 DRD3 HTR1B
24 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.77 DRD2 DRD3 DRD4
25 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.76 DRD3 DRD5 OPRM1
26 behavioral response to cocaine GO:0048148 9.76 DRD2 DRD3 DRD4 OPRK1
27 regulation of smooth muscle contraction GO:0006940 9.74 CHRNA3 CHRNB4
28 vasoconstriction GO:0042310 9.74 HTR1B SLC6A4
29 estrous cycle GO:0044849 9.74 OPRK1 OPRM1
30 opioid receptor signaling pathway GO:0038003 9.74 OPRD1 OPRK1 OPRM1
31 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.73 DRD2 HTR1B
32 neurotransmitter biosynthetic process GO:0042136 9.73 SLC6A3 SLC6A4
33 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.73 DRD2 DRD5
34 sensory perception GO:0007600 9.73 OPRK1 OPRM1
35 negative regulation of voltage-gated calcium channel activity GO:1901386 9.73 DRD2 DRD4
36 dopamine receptor signaling pathway GO:0007212 9.73 DRD2 DRD3 DRD4 DRD5
37 ammonium transmembrane transport GO:0072488 9.72 SLC6A3 SLC6A4
38 positive regulation of renal sodium excretion GO:0035815 9.72 DRD2 DRD3
39 regulation of synaptic transmission, GABAergic GO:0032228 9.72 CNR1 DRD2
40 ethanol oxidation GO:0006069 9.72 ADH1A ADH4
41 behavior GO:0007610 9.72 HTR1B OPRK1
42 behavioral response to nicotine GO:0035095 9.72 CHRNA3 CHRNA5 CHRNB4
43 response to nicotine GO:0035094 9.72 CHRNA5 CHRNB4 CNR1 DRD2 SLC6A3
44 regulation of dopamine metabolic process GO:0042053 9.71 DRD4 SLC6A3
45 adenohypophysis development GO:0021984 9.71 DRD2 SLC6A3
46 monoamine transport GO:0015844 9.71 SLC6A3 SLC6A4
47 dopamine catabolic process GO:0042420 9.71 MAOA SLC6A3
48 regulation of cAMP metabolic process GO:0030814 9.7 DRD2 DRD3
49 dopamine uptake involved in synaptic transmission GO:0051583 9.7 SLC6A3 SLC6A4
50 alcohol metabolic process GO:0006066 9.7 ADH1A ADH4

Molecular functions related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.97 CNR1 DRD2 DRD3 DRD4 DRD5 HTR1B
2 signal transducer activity GO:0004871 9.86 CNR1 DRD2 DRD3 DRD4 DRD5 HTR1B
3 extracellular ligand-gated ion channel activity GO:0005230 9.71 CHRNA3 CHRNA5 CHRNB4
4 ligand-gated ion channel activity GO:0015276 9.7 CHRNA3 CHRNA5 CHRNB4
5 neuropeptide binding GO:0042923 9.67 OPRD1 OPRK1 OPRM1
6 acetylcholine binding GO:0042166 9.65 CHRNA3 CHRNA5 CHRNB4
7 acetylcholine-gated cation-selective channel activity GO:0022848 9.63 CHRNA3 CHRNA5 CHRNB4
8 acetylcholine receptor activity GO:0015464 9.61 CHRNA3 CHRNA5 CHRNB4
9 retinol dehydrogenase activity GO:0004745 9.58 ADH1A ADH4
10 neurotransmitter:sodium symporter activity GO:0005328 9.58 SLC6A3 SLC6A4
11 opioid receptor activity GO:0004985 9.58 OPRD1 OPRK1 OPRM1
12 alcohol dehydrogenase (NAD) activity GO:0004022 9.57 ADH1A ADH4
13 monoamine transmembrane transporter activity GO:0008504 9.56 SLC6A3 SLC6A4
14 alcohol dehydrogenase activity, zinc-dependent GO:0004024 9.55 ADH1A ADH4
15 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.54 DRD2 DRD3 DRD4
16 dopamine:sodium symporter activity GO:0005330 9.51 SLC6A3 SLC6A4
17 dopamine neurotransmitter receptor activity GO:0004952 9.46 DRD2 DRD3 DRD4 DRD5
18 dopamine binding GO:0035240 9.35 DRD2 DRD3 DRD4 DRD5 SLC6A3
19 drug binding GO:0008144 9.17 CHRNB4 CNR1 DRD2 DRD3 DRD4 HTR1B

Sources for Substance Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....